The benefit of treatment with quizartinib and subsequent bridging to HSCT for FLT3-ITD(+) patients with AML.
Mark J. Levis
Consultant or Advisory Role - Ambit BioSciences (U)
Giovanni Martinelli
No relevant relationships to disclose
Alexander E. Perl
Consultant or Advisory Role - Ambit BioSciences (U); Astellas Pharma (U)
Hervé Dombret
No relevant relationships to disclose
Bjoern Steffen
No relevant relationships to disclose
Philippe H. Rousselot
No relevant relationships to disclose
Elihu Estey
No relevant relationships to disclose
Neil P. Shah
Research Funding - Ambit BioSciences
Guy Gammon
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
Denise Trone
Employment or Leadership Position - Ambit BioSciences
Jorge E. Cortes
Consultant or Advisory Role - Ambit BioSciences (U); Astellas Pharma (U)
Research Funding - Ambit BioSciences; Astellas Pharma